Scholarlink

Background/objectives <p>No data regarding the outcomes of GATT in patients with highly advanced glaucoma are available. The aim of this study is to fill in this gap.</p> Subjects/methods <p>This is a multicentre, retrospective, and case-control study including highly advanced glaucoma patients (HVF Mean Deviation, MD &lt; −20 dB, study group–SG) and controls (CG: MD &gt; −20 dB). Sixty eyes (31 GATT stand-alone and 29 Phaco-GATT eyes) were included in each group. The SG and CG were compared until 12 months of follow-up, and survival analyses were performed.</p> Results <p>The preoperative MD was −25.95 ± 3.64 dB in the SG and −7.96 ± 5.25 dB in the CG (p &lt; 0.001). Preoperative IOP was 21.5 ± 8.2 mmHg in the SG on 3.4 ± 1.4 medications, and 20.8 ± 7.3 mmHg in the CG (p = 0.6) on 3.0 ± 0.9 medications (p = 0.1). At the 12-month visit, IOP was reduced by 39.1 ± 26.6% in the SG and 36.0 ± 18.7% in the CG (p = 0.4), and the number of preoperative medications was reduced by 62.2 ± 33.2% in the SG and 65.5 ± 37.4% in the CG (p = 0.6), with 93.3% of the eyes in the SG and 90.0% of the eyes in the CG having an IOP ≤ 14 mmHg, with or without medication (p = 0.5). No serious adverse events were observed in any of the groups.</p> Conclusion <p>GATT is a safe and effective surgical option for patients with highly advanced glaucoma.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Gonioscopy-assisted transluminal trabeculotomy outcomes in patients with highly advanced glaucoma

  • 期刊论文

  • 发表日期：

    2025年7月8日

查看全文
  • Leopoldo Magacho,
  • Cláudia Gomide Vilela de S. Franco,
  • Eduardo Akio I,
  • Ana Cláudia Alves Pereira,
  • Bruno Teno,
  • Francisco Lucena-Neto,
  • Bruno M. Faria,
  • Júlia Maggi Vieira,
  • Marcos Pereira Vianello,
  • Fábio N. Kanadani

摘要

Background/objectives

No data regarding the outcomes of GATT in patients with highly advanced glaucoma are available. The aim of this study is to fill in this gap.

Subjects/methods

This is a multicentre, retrospective, and case-control study including highly advanced glaucoma patients (HVF Mean Deviation, MD < −20 dB, study group–SG) and controls (CG: MD > −20 dB). Sixty eyes (31 GATT stand-alone and 29 Phaco-GATT eyes) were included in each group. The SG and CG were compared until 12 months of follow-up, and survival analyses were performed.

Results

The preoperative MD was −25.95 ± 3.64 dB in the SG and −7.96 ± 5.25 dB in the CG (p < 0.001). Preoperative IOP was 21.5 ± 8.2 mmHg in the SG on 3.4 ± 1.4 medications, and 20.8 ± 7.3 mmHg in the CG (p = 0.6) on 3.0 ± 0.9 medications (p = 0.1). At the 12-month visit, IOP was reduced by 39.1 ± 26.6% in the SG and 36.0 ± 18.7% in the CG (p = 0.4), and the number of preoperative medications was reduced by 62.2 ± 33.2% in the SG and 65.5 ± 37.4% in the CG (p = 0.6), with 93.3% of the eyes in the SG and 90.0% of the eyes in the CG having an IOP ≤ 14 mmHg, with or without medication (p = 0.5). No serious adverse events were observed in any of the groups.

Conclusion

GATT is a safe and effective surgical option for patients with highly advanced glaucoma.